옵션 체인은 다양한 행사가격과 만기일에 대한 Geovax Labs의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Geovax Labs에 대한 시장 심리를 평가합니다..

Geovax Labs (NASDAQ:GOVX) 주식, 옵션 체인

Geovax Labs

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

Broad U.S. Equity ETFs

Tech

ETFs

APDN

ASTS

CING

CRWD

INDO

SERV

VRAX

ZAPP

매일의 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보자. 현재 가격과 연간 실적은 8월 30일을 기준으로 하며 배당금은 포함되지 않았다. 4월 검색결과는 추적되지 않았다.

단독: 2024년 8월 벤징가 프로에서 가장 검색량이 많았던 상위 20개 티커는?

Biotech

News

Health Care

After-Hours Center

Movers

지오백스 랩스(NASDAQ:GOVX)의 주가는 수요일 뉴욕 시장 마감을 앞두고 급등했고, 미시간주 웨인(Wayne) 카운티에서 2022년 이후 첫 번째 엠폭스(mpox, 원숭이두창) 사례가 확인됐다는 보도가 나온 후 시간외 거래에서 계속해서 반등했다.

지오백스의 주식, 수요일 시장 마감 직전부터 시간외 거래까지 급등 지속: 무슨 일이?

Geovax Labs Inc

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $18 price target.

Price Target

Analyst Ratings

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $18 Price Target

<a href="https://geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs" title="https://geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs">https://geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs</a>

GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs

Harnessing AI to Revolutionize Vaccine and Therapy Development
ATLANTA, GA, February 3, 2025 — GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>), a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J. Trump's Stargate Initiative, which aims to harness advanced technologies including Artificial Intelligence (AI) to strengthen U.S. healthcare, biosecurity, and global innovation leadership. This announcement aligns with GeoVax's commitment to leveraging AI across its vaccine and cancer immunotherapy programs to accelerate research, optimize operations, and deliver life-saving solutions.
Revolutionizing Healthcare with AI
GeoVax has embedded AI into its platforms for vaccine development and cancer immunotherapy, enabling groundbreaking advances:
<ul>
<li>Vaccine Development: AI drives target discovery and design for vaccines using the Modified Vaccinia Ankara (MVA) platform, including GEO-CM04S1, GeoVax's next-generation vaccine for COVID-19, and vaccines for Mpox and Smallpox. AI predicts pathogen mutations, ensuring long-lasting and variant-proof vaccines.</li>
<li>Cancer Immunotherapy: AI optimizes GeoVax's Gene-Directed Enzyme Prodrug Therapy (GDEPT) for solid tumors, including predictive modeling of tumor microenvironments, real-time adjustment of protocols to maximize therapeutic efficacy, and identifying synergistic combinations with immune checkpoint inhibitors.</li>
<li>Clinical Targeting: AI-powered analytics will refine patient stratification, ensuring that GeoVax's therapies reach underserved populations most in need, aligning with the initiative's national focus to maximize therapeutic efficacy.</li>
<li>Manufacturing and Operations: AI improves GeoVax's vaccine production scalability and supply chain management, ensuring timely delivery to strategic stockpiles.</li>
</ul>
Aligned with the Stargate Vision
President Trump's Stargate Initiative, supported by up to $500 billion in private-sector investment, represents a bold step forward in embracing transformative technologies. GeoVax proudly aligns with this vision, advancing U.S. healthcare innovation and pandemic preparedness.
David Dodd, GeoVax Chairman and CEO, stated: "President Trump's Stargate Initiative exemplifies leadership in harnessing AI to address critical healthcare challenges. GeoVax is honored to support this initiative, highlighting its application of AI to develop vaccines and therapies that save lives and enhance biosecurity. We are proud to contribute to a future where the United States leads the world in healthcare innovation."
Building on Operation Warp Speed's Legacy
GeoVax's efforts reflect the spirit of President Trump's Operation Warp Speed, which accelerated COVID-19 vaccine development and deployment. By integrating AI into its research and operational strategies, GeoVax aims to continue pushing the boundaries of what is possible in medical science.
A Commitment to Life-Saving Innovation
GeoVax remains steadfast in its mission to develop innovative vaccines and immunotherapies, leveraging the power of AI to meet the healthcare needs of today and prepare for the challenges of tomorrow. With AI now embedded in its processes, GeoVax anticipates shorter development timelines, increased efficiency in clinical trials, and enhanced capacity to deliver life-saving therapies globally. Collaborations with academic institutions, industry partners and federal agencies will further amplify the reach and impact of GeoVax's innovative programs under the Stargate framework. AI-enabled supply chain optimization will further ensure efficient vaccine distribution to high-priority populations and regions.

General

GeoVax Announces Strategic Integration Of AI In Support Of President Trump's Stargate Initiative; Harnessing AI To Revolutionize Vaccine And Therapy Development

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

AEMD

CMRX

MRNA

TNXP

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

<a href="https://geovax.com/investors/press-releases/geovax-advanced-mva-manufacturing-process-aimed-to-enhance-vaccine-supply-worldwide">https://geovax.com/investors/press-releases/geovax-advanced-mva-manufacturing-process-aimed-to-enhance-vaccine-supply-worldwide</a>
Process Expected to Increase Production Yield, Flexibility at Lower Cost
Atlanta, GA – January 27, 2025 – GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>), a clinical-stage biotechnology company specializing in vaccines and immunotherapies, has shared updates about its development-stage advanced Modified Vaccinia Ankara (MVA) vaccine manufacturing process. This anticipated process provides the potential to not only address today's pressing health challenges but also paves the way for more efficient, flexible and lower-cost MVA-vaccine manufacturing.
The Power and Versatility of the MVA Platform
The MVA platform is uniquely designed to incorporate multiple antigens into a single vaccine. This versatility allows GeoVax to develop vaccines targeting multiple aspects of a single pathogen or several pathogens simultaneously. Originally developed as a safer smallpox vaccine, the MVA platform offers distinct advantages, including:
<ul>
<li>Protection against diseases such as Mpox and smallpox.</li>
<li>Multi-antigen vaccines like GEO-CM04S1, which targets both the Spike (S) and Nucleocapsid (N) antigens of SARS-CoV-2.</li>
<li>Stability under minimal refrigeration and the potential for freeze-drying (lyophilization), simplifying distribution in resource-limited settings.</li>
</ul>
Advancing MVA Manufacturing
Current vaccine manufacturing methods rely on Chicken Embryo Fibroblast (CEF) cells, requiring pathogen-free eggs. This process is costly, time-consuming, and dependent on limited egg supplies, providing barriers to rapid, real-time MVA manufacturing, as well as hindering the flexibility necessary to establish local MVA manufacturing of critically important vaccines. &nbsp;GeoVax is addressing these barriers through an advanced MVA Manufacturing process utilizing an avian cell line licensed from ProBioGen AG (Berlin). Key features include:
<ul>
<li>A continuous avian suspension cell line process that eliminates the need for pathogen-free eggs.</li>
<li>Compatibility with standard manufacturing equipment, reducing setup time, simplifying the MVA manufacturing process, increasing scalability and lowering manufacturing costs.</li>
</ul>
This advanced MVA manufacturing process is expected to significantly simplify vaccine production, particularly in middle- and low-income regions where supply chain issues often hinder access to critical vaccines.
Addressing Global Health Needs
"Our advanced MVA manufacturing process represents not only a transformative manufacturing advance but also addresses a public health imperative," said David Dodd, Chairman and CEO of GeoVax. "By tackling disease protection, logistical hurdles, and manufacturing challenges, we aim to empower regions like Africa with the tools needed to combat current and future health crises."
GeoVax's MVA vaccines have demonstrated robust performance in clinical trials, with ongoing Phase 2 studies for GEO-CM04S1, its COVID-19 vaccine candidate, showing broad and durable immune responses. Supported by its BARDA Project NextGen Award and partnerships with leading manufacturing and development organizations, GeoVax is positioned to enhance vaccine access and delivery on a global scale.
Recent Conference Presentations
GeoVax CEO David Dodd recently presented the company's strategic initiatives and the potential of GEO-MVA at:
<ul>
<li>Biotech Showcase: January 14, 2025</li>
<li>Emerging Growth Conference: January 16, 2025</li>
</ul>

GeoVax Shares Update On Its Advanced MVA Manufacturing Process, Aimed To Enhance Vaccine Supply Worldwide

<a href="https://geovax.com/investors/press-releases/geovax-announces-major-gedeptin-milestone-with-plans-of-phase-2-trial" title="https://geovax.com/investors/press-releases/geovax-announces-major-gedeptin-milestone-with-plans-of-phase-2-trial">https://geovax.com/investors/press-releases/geovax-announces-major-gedeptin-milestone-with-plans-of-phase-2-trial</a>

GeoVax Announces Major Gedeptin Milestone With Plans Of Phase 2 Trial

GeoVax Receives Notice Of Allowance For Patent Application Titled 'Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles.'

<a href="https://worldhealthorg.shinyapps.io/mpx_global/" title="https://worldhealthorg.shinyapps.io/mpx_global/">https://worldhealthorg.shinyapps.io/mpx_global/</a>

World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

GOVXW

GeoVax Reports Interim Data For Phase 2 Trial Of COVID-19 Booster Vaccine GEO-CM04S1 In CLL Patients; DSMB Recommends Continued Enrollment As GEO-CM04S1 Outperforms mRNA Vaccine In Immune Response Evaluation

GeoVax Labs Received Notice From Nasdaq Notifying The Company That, Co. Complies With Stockholders' Equity Listing Rule

<h3>Gainers</h3>
<ul>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares rose 22.7% to $2.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $331.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 19.74% to $2.46. The market value of their outstanding shares is at $31.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares increased by 18.48% to $2.5. The market value of their outstanding shares is at $29.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) shares rose 16.66% to $157.64. The company's market cap stands at $19.4 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 15.62% to $0.78. The market value of their outstanding shares is at $11.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock increased by 12.61% to $8.66. The company's market cap stands at $286.3 million. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares decreased by 85.6% to $0.39 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.5 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock decreased by 72.24% to $0.44. The market value of their outstanding shares is at $2.5 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock fell 23.4% to $0.05. The company's market cap stands at $2.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares declined by 20.03% to $0.21. The market value of their outstanding shares is at $32.1 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares declined by 20.0% to $2.6. The company's market cap stands at $22.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 17.6% to $0.51. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CERO

CLDI

ENSC

GCTK

KAPA

LXEO

MRSN

NTRA

SYRS

VRPX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

GeoVax Labs shares are trading lower. The company reported Q3 financial results.

Press Releases

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

Earnings

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Presenting on the Emerging Growth Conference 78 Day 1 on January 15 Register Now

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Comments

Geovax Labs

Geovax Labs (GOVX) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌